Why the study?
Clinical studies suggest mavacamten monotherapy is efficacious with a favorable safety profile in obstructive HCM, but limited evidence exists regarding monotherapy in real-world studies.
Does mavacamten monotherapy improve symptoms and cardiac function in real-world adult patients with obstructive hypertrophic cardiomyopathy compared to mavacamten with background therapy?
Does mavacamten monotherapy improve symptoms and cardiac function in real-world adult patients with obstructive hypertrophic cardiomyopathy compared to mavacamten with background therapy?
Real-world evidence demonstrates that mavacamten monotherapy provides significant improvements in symptoms and LVOT gradients comparable to mavacamten combined with background therapy, with an acceptable safety profile.
Answers are grounded in this paper and cite their sources.
Real-world mavacamten monotherapy data in obstructive HCM remain hypothesis-generating; prospective trials needed before practice change.
BACKGROUND: Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy is efficacious and has a favorable safety profile, but limited evidence exists regarding monotherapy in real-world studies. This analysis aimed to describe the effectiveness and safety outcomes of mavacamten monotherapy in the real-world COLLIGO-HCM study (Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy). METHODS: Patient-level data recorded between April 2022 and February 2025 at 7 sites across 5 countries were extracted. Adult patients with a diagnosis of HCM from 2018 onwards were eligible for inclusion if they had ≥1 mavacamten prescription after the date of diagnosis. Patients were categorized based on background therapy status during mavacamten treatment: mavacamten monotherapy or mavacamten with background therapy (down-titration or no dose modification). RESULTS: Overall, 278 patients were included and received mavacamten (mavacamten monotherapy, n=88; mavacamten with background therapy, n=190). At month 9, most patients achieved ≥1 New York Heart Association class improvement from baseline (mavacamten monotherapy, 60.0%; mavacamten with background therapy, 61.0%). Improvements in resting and Valsalva left ventricular outflow tract gradients from baseline to month 9 were observed in both subgroups; mean left ventricular ejection fraction through month 9 remained ≥62.0% with mavacamten monotherapy and ≥61.4% with mavacamten with background therapy. Two patients in the mavacamten monotherapy subgroup and 1 patient in the mavacamten with background therapy subgroup permanently discontinued treatment owing to left ventricular ejection fraction <50%. CONCLUSIONS: Mavacamten monotherapy was associated with improvements in cardiac function and symptoms, and positive benefits to the risk profile over a 9-month follow-up period; this was consistent with improvements observed in patients treated with mavacamten with background therapy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06372457.
No takes yet. Share an insight, caveat, or question.
Bilen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: